The National Institute on Aging (part of NIH) has selected oxaloacetic acid (benaGeneTM) for long-term testing under the Interventions Testing Protechol (ITP). NIA's ITP is a multi-institutional study investigating treatments with the potential to extend lifespan and delay disease and dysfunction. Oxaloacetic acid is in Cohort 4.